Showing results (61-70 of 482) with videos related to

Sort By:
Pageof 49
Cardiovascular Revascularization Medicine : Including Molecular Interventions|March 21, 2018
Anatomical and procedural determinants of ambulatory blood pressure lowering following catheter-based renal denervation using radiofrequencyLucas Lauder, Sebastian Ewen, Abraham R Tzafriri, et al.
JACC. Advances|February 22, 2025
Long-Term, Patient-Level Analysis of Radiofrequency Renal Denervation in the SYMPLICITY Clinical Trial ProgramFelix Mahfoud, Raymond R Townsend, David E Kandzari, et al.
Hypertension (Dallas, Tex. : 1979)|November 21, 2024
Response of Blood Pressure to Renal Denervation Is Not Associated With Genetic VariantsChristian Delles, Roland E Schmieder, Rónán Daly, et al.
Clinical Cardiology|January 27, 2012
Inadequate reporting of concomitant drug treatment in cardiovascular interventional head-to-head trialsFelix Mahfoud, Michael Böhm, Magnus Baumhäkel
Current Medical Research and Opinion|April 10, 2024
The current position of β-blockers in hypertension: guidelines and clinical practiceFelix Mahfoud, Jiguang Wang, Saumitra Ray
Acta Neurochirurgica|October 7, 2009
Intracranial pressure pulse amplitude during changes in head elevation: a new parameter for determining optimum cerebral perfusion pressure?Felix Mahfoud, Jürgen Beck, Andreas Raabe
Korean Circulation Journal|February 4, 2017
Renal Denervation for Chronic Heart Failure: Background and Pathophysiological RationaleMichael Böhm, Sebastian Ewen, Felix Mahfoud
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|April 28, 2026
Catheter-directed thrombectomy in acute pulmonary embolism and angiographic signs of chronic thromboembolic pulmonary diseaseParham Shahidi, Luise Mentzel, Lucas Lauder, et al.
European Heart Journal|July 16, 2020
Randomized trials of invasive cardiovascular interventions that include a placebo control: a systematic review and meta-analysisLucas Lauder, Bruno R da Costa, Sebastian Ewen, et al.
European Heart Journal|December 8, 2022
Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trialMichael Bhm, Stefan Anker, Felix Mahfoud, et al.
Pageof 49